Scarica l'app Stockscreener
1.58
5.39%
-0.09
Dopo l'orario di chiusura:
1.59
0.01
+0.63%
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Is a relief rally coming for Ovid Therapeutics Inc. holdersPortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Combining machine learning predictions for Ovid Therapeutics Inc.2025 Volatility Report & Consistent Growth Stock Picks - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - The Globe and Mail
Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in
Market reaction to Ovid Therapeutics Inc.’s recent newsRate Hike & Breakout Confirmation Alerts - newser.com
Ovid spikes as Wedbush moves to Outperform on lead asset - MSN
Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener
Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com
What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in
Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com
Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business
What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm
Ovid Therapeutics Inc. (OVID) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance
Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating - MarketScreener
What’s next for Ovid Therapeutics Inc. stock priceJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Ovid Therapeutics Sets Market Trends with Successful Trials - Kalkine Media
Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Forecasting Ovid Therapeutics Inc. price range with options data2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Why Ovid Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
Ovid Therapeutics rises on $175 million placing and research update - The Pharma Letter
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results - Yahoo Finance
Ovid announces positive topline results for the - GlobeNewswire
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Ovid Therapeutics Secures $175.1M in Private Placement - TipRanks
Ovid Therapeutics Inc. announced that it expects to receive $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC - MarketScreener
Ovid Therapeutics Stock: Analyzing Market Movement - timothysykes.com
Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders - Seeking Alpha
OVID Stock Surge: Opportunity or Risk? - StocksToTrade
Ovid Therapeutics Inc. (OVID) Stock: Rallies as Major Investors Join $175M Private Placement - parameter.io
Ovid Therapeutics Inc. (OVID) Stock: Soars on $81M Initial Funding, PIPE Could Reach $175M - CoinCentral
Wedbush Adjusts Ovid Therapeutics Price Target to $5 From $3, Maintains Outperform Rating - MarketScreener
Ovid Therapeutics (OVID) Surges After Positive Study Results - GuruFocus
Transcript : Ovid Therapeutics Inc.Special Call - MarketScreener
Ovid Therapeutics Surges: Is It a Buy? - StocksToTrade
Ovid Therapeutics Rockets 19% on Game-Changing Epilepsy Drug Breakthrough – Why This Could Shake Up Brain Health Investing - RagingBull
Ovid rises after positive results from epilepsy study (OVID) - Seeking Alpha
Ovid Therapeutics Surge: Market Moves and Metrics - timothysykes.com
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why - Stocktwits
Ovid Therapeutics Raises $175 Million Through PIPE Financing - Finimize
Ovid Therapeutics (OVID) Secures $175M in PIPE Financing Deal - GuruFocus
Ovid Therapeutics Reports 'Positive' Topline Data on OV329 for Drug Resistant Epilepsies - MarketScreener
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):